Target intelligence / Profile preview

Synaptotagmin 4 (SYT4)

Target
SYT4
Molecular classification
Synaptotagmin family, Vesicle-associated membrane protein, Calcium sensor (non-classical due to altered Ca^2+-binding domains), Immediate early gene (activity-regulated)
01

Overview

Synaptotagmin 4 is a vesicle-associated membrane protein and a non-classical calcium sensor predominantly expressed in the nervous system, including neurons and astrocytes. It contains two C2 domains: the C2A domain has a loss-of-function mutation that diminishes calcium-binding capacity, while the C2B domain retains calcium-dependent properties, enabling it to participate in homo- and hetero-oligomerization with other synaptotagmins. SYT4 modulates membrane fusion, regulates exocytosis, and is upregulated in response to neuronal activity (such as seizures). It acts through interaction with SNARE proteins and is required for proper synaptic growth, plasticity, and regulated neurotransmitter (especially glutamate) release from astrocytes. Dysregulation of SYT4 may contribute to neurological diseases and is studied in relation to brain development, activity-dependent synaptic adaptations, and neuroendocrine signaling[1][2][4][5][7].

Other names
Syt4SYT4Synaptotagmin-IV
02

Mechanism of action

For therapy, not well defined. Research suggests possible negative modulation of vesicle exocytosis and calcium-dependent neurotransmitter/peptide release, but no drug-based mechanisms currently described[1][4][5][7].

03

Biological functions

Regulation of vesicle fusion/exocytosisCalcium signaling (with altered calcium sensitivity relative to other synaptotagmins)Negative regulation of catecholamine secretionPositive regulation of dendrite extensionRegulation of synaptic growth and plasticityModulation of learning and memory (by influencing long-term potentiation)Regulation of glutamate release from astrocytes
04

Disease associations

Pontocerebellar hypoplasia, type 2EPheochromocytomaPotentially involved in neurological disorders and synaptic plasticity deficitsLinked (in animal models) to autism spectrum disorder via interactions with neuroligin pathways
05

Safety considerations

Non-classical calcium-binding complicates targeting/calcium signalingActivity-dependent regulation and possible redundant functions with other synaptotagmin isoformsDual roles in both excitatory and inhibitory pathways could affect specificity
06

Interacting drugs

None clearly established; research has not yet identified clinical drugs directly targeting Synaptotagmin 4. Its pathway is targeted by pharmacological research, but no approved drugs are listed.
07

Biomarkers

None currently recognized for patient selection or efficacy monitoring

Beyond the preview

Go deeper on Synaptotagmin 4 (SYT4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synaptotagmin 4 (SYT4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call